ROCKLAND, Mass.--(BUSINESS WIRE)--BioSphere Medical, Inc. (NASDAQ: BSMD), a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations, announced today that the Centers for Medicare and Medicaid Services (CMS) issued its Final Rule regarding hospital outpatient reimbursement for uterine fibroid embolization (UFE) and, accordingly, will increase such reimbursement by 113 percent to $5,639 per procedure from $2,642 per procedure beginning January 1, 2008.
